Sarah Krepp Sells 13,165 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sarah Krepp sold 13,165 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $492,765.95. Following the completion of the sale, the insider directly owned 140,769 shares in the company, valued at approximately $5,268,983.67. This trade represents a 8.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Sarah Krepp also recently made the following trade(s):

• On Monday, December 1st, Sarah Krepp sold 221 shares of Liquidia stock. The stock was sold at an average price of $32.19, for a total transaction of $7,113.99.

Liquidia Price Performance

Shares of LQDA opened at $39.99 on Thursday. The firm has a market capitalization of $3.48 billion, a price-to-earnings ratio of -27.77, a PEG ratio of 0.65 and a beta of 0.48. The firm’s fifty day simple moving average is $32.41 and its 200-day simple moving average is $25.68. Liquidia Corporation has a twelve month low of $11.26 and a twelve month high of $40.53. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The firm had revenue of $54.34 million for the quarter, compared to analyst estimates of $18.86 million. The company’s revenue for the quarter was up 1106.7% compared to the same quarter last year. Equities analysts forecast that Liquidia Corporation will post -1.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on LQDA. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $47.00 price target on shares of Liquidia in a report on Tuesday, November 4th. Needham & Company LLC upped their target price on shares of Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Wells Fargo & Company started coverage on shares of Liquidia in a research report on Monday, October 20th. They issued an “overweight” rating and a $31.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $39.67.

Institutional Trading of Liquidia

Several institutional investors and hedge funds have recently bought and sold shares of LQDA. Whitcomb & Hess Inc. boosted its stake in Liquidia by 2.0% during the 3rd quarter. Whitcomb & Hess Inc. now owns 28,385 shares of the company’s stock worth $645,000 after purchasing an additional 558 shares during the period. Alliancebernstein L.P. increased its stake in Liquidia by 1.4% in the third quarter. Alliancebernstein L.P. now owns 67,050 shares of the company’s stock valued at $1,525,000 after purchasing an additional 900 shares during the period. Ballentine Partners LLC raised its holdings in shares of Liquidia by 10.2% in the second quarter. Ballentine Partners LLC now owns 12,139 shares of the company’s stock valued at $151,000 after buying an additional 1,119 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its stake in shares of Liquidia by 24.0% during the second quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock worth $77,000 after buying an additional 1,200 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Liquidia during the third quarter worth about $30,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Recent patent and court wins reduce execution and IP risk for Liquidia’s inhaled treprostinil program, supporting upside potential for commercialization. Seeking Alpha – Patent Update
• Positive Sentiment: Analyst sentiment has been upgraded recently (multiple firms raising targets and issuing Buy/Strong Buy ratings), which can attract fresh capital and lend support to the rally. Benzinga – Analyst Expectations
• Positive Sentiment: Short interest fell materially in December (reported ~18% decline), lowering potential downward pressure from short sellers and reducing immediate squeeze/volatility risk. MarketBeat – Short Interest & Court Coverage
• Neutral Sentiment: Analyst/industry write-ups note the company has won many patent battles but caution the “war is not yet won,” signaling that legal/IP progress is positive but some uncertainties remain. Seeking Alpha – Balanced Take
• Negative Sentiment: Large, coordinated insider selling occurred on Jan. 12: CEO Roger Jeffs (66,610 sh, ~$2.49M), CFO Michael Kaseta (36,932 sh, ~$1.38M), General Counsel Russell Schundler (27,289 sh, ~$1.02M) and several other insiders (collectively selling millions of dollars of stock). While insiders still retain significant stakes, the volume and scale of sales may be viewed as profit‑taking and can weigh on sentiment. MarketBeat – Insider Trades

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).